FIG. 1




Normal
Vldlr -/-
Ranibizumab 50ng/eye
HL-217 3.0mg/ml
Fundus microscopy
FITC-dextran perfused whole mount retina
Hoechst 33342 perfused whole mount retina
Fluorescence intensity(AU)
0
2
4
6
#
*
Normal
Vldlr -/-
Ranibizumab
HL-217 3.0mg/ml

FIG. 2


Normal
Vldlr -/-
Ranibizumab 50ng/eye
HL-217 3,0mg/ml
Isolectin B4 staining (vessel marker)
H&E staining
High magnification of upper inlet box